Final analysis results will be announced through specialized academic journals, and phase 3 will begin in the first half of next year.
[서울파이낸스 김현경 기자] Daewoong Pharmaceutical announced on the 23rd the top line results of the 2a clinical trial, saying that Hoystar tablet (ingredient name chamostatmesylate) eliminated the corona 19 virus faster than placebo. The top line is rough information that can be used to determine the success or failure of a clinical trial.
According to Daewoong Pharmaceutical, the clinical trial was conducted on 89 mild or asymptomatic confirmed patients hospitalized for Corona 19. The research team, Myung-don Oh, a professor of infectious medicine at Seoul National University, assigned a total of 81 subjects to the Hoystar tablet administration group, 41 subjects (average age 55 years), and placebo administration group 40 subjects (average age 43 years), excluding dropouts. Evaluated.
Daewoong Pharmaceutical explained that the virus removal rate tended to be faster in the Hoystar group than in the placebo group. As a result of the analysis of the ordinal scale and the NEWS score, the time taken to improve the patient’s clinical symptoms showed faster recovery in the Hoystar group.
Hoy Star Tablet is a specialty medicine used for chronic pancreatitis and is being developed by Daewoong Pharmaceutical as a treatment for COVID-19. It is an inhibitor of TMPRSS2, a mechanism that prevents virus from entering the cell without directly killing the virus.
Daewoong Pharmaceutical will officially publish the final results in an academic journal based on further analysis and research by experts. Jeon Seung-ho, president of Daewoong Pharmaceutical, said, “We will quickly obtain the same results in large-scale patients and secure the results of phase 3 clinical trials within the first half of next year.”
On the 17th, Daewoong Pharmaceutical received approval from the Ministry of Food and Drug Safety to merge the phase 2 clinical trials of Hoystar into phase 2.3. Accordingly, a clinical trial for 1,000 mild patients was initiated. In the case of niclosamide injection, which is being developed by Daewoong Pharmaceuticals as a treatment for Corona 19 in addition to Hoy Star, it will finish phase 1 clinical trials in India and abroad, and prepare for multi-national phase 2 clinical trials.
Copyright © Seoul Finance Unauthorized reproduction and redistribution prohibited